Introduction
dementia
AMYLOID, AMYLOID DEPOSITION, ALZHEIMER DISEASE (AD)
Amyloid deposition in the brain is one of the main hallmarks of Alzheimer disease (AD) and is considered one of the strongest risk factors of dementia.In the United States, the IDEAS study provided strong evidence on the association of amyloid PET with subsequent changes in patients’ diagnosis and management in a large (n = 11 409) but selected cohort consisting of Medicare beneficiaries 65 years or olderThe Amyloid Imaging to Prevent Alzheimer’s Disease Diagnostic and Patient Management Study (AMYPAD-DPMS) was designed as a prospective, multicenter, randomized clinical trialIn the present work, we investigated whether participants allocated to undergo amyloid PET early in their diagnostic workup received an etiological diagnosis with very high diagnostic confidence after 3 months more frequently than those who had not undergone amyloid PET yet. Moreover, we also assessed whether early amyloid PET is associated with more frequent changes in diagnosis, diagnostic confidence, and treatment plan. Finally, we examined the real-world use and clinical effect of unrestricted amyloid PET imaging in a free-choice group.